MedTrace Logo

Cysteine-lowering Treatment With Mesna

NCT04449536 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2022-05-19

No results posted yet for this study

Summary

The primary objective of this study is to determine the efficacy of the drug Mesna® (Uromitexan) in healthy participants with overweight or obesity with respect to change in plasma concentrations of total cysteine, following single ascending doses of oral Mesna.

Conditions

Interventions

DRUG

Mesna

Administration of a single oral dose, using film-coated tablets of either 400 mg or 600 mg or a combination of maximum 3 tablets up to a maximum of 1600 mg

Sponsors & Collaborators

  • Oslo University Hospital

    collaborator OTHER

  • University of Oxford

    collaborator OTHER

  • University of Oslo

    lead OTHER

Principal Investigators

  • Kjetil Retterstøl, MD, PhD · University of Oslo

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-02
Primary Completion
2021-10-21
Completion
2021-10-21

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04449536 on ClinicalTrials.gov